Everything published about SS-31: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 50 mg | from 3 600 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
SS-31, known pharmaceutically as elamipretide, is a four-amino-acid peptide that targets mitochondrial membrane biology. It interacts with cardiolipin, a lipid important for the organisation of mitochondrial energy-producing machinery.
A mitochondria-targeted peptide that interacts with cardiolipin. A pharmaceutical formulation has US accelerated approval for improving muscle strength in Barth syndrome in patients weighing at least 30 kg.
A mitochondria-targeted peptide with a specific clinical application and an active research story around cellular energy.
Laboratory studies investigate mitochondrial membrane stability and energy production. In Barth syndrome, extended follow-up found improved muscle strength; the initial controlled walking-distance and fatigue endpoints were not met. Broader energy and healthy-ageing uses remain under investigation.
Commonly discussed research-community protocols: 5 mg subcutaneously daily for 22 days, with three cycles yearly. Other community protocols describe 4–10 mg daily. For the licensed Barth-syndrome formulation: 40 mg daily for eligible patients weighing at least 30 kg; 20 mg daily for adults with severe renal impairment who are not on dialysis. The licensed formulation and research-vial cycles are distinct.
Injection-site reactions are common; hypersensitivity can occur. Kidney function affects the licensed dosing regimen.
SS-31 focuses on cardiolipin and mitochondrial membrane function. MOTS-c acts as a metabolic stress signal. They represent different approaches to mitochondrial research.
from 3 600 000 ₫ for 50 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.